In the Original Investigation titled “Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors,”[1] published February 24, 2022, an Additional Information section was added to indicate that the study was endorsed by the Italian Association for Neuroendocrine Tumors (It.a.net). This article has been corrected.[1]
Authors: Sara Pusceddu; Natalie Prinzi; Salvatore Tafuto; Toni Ibrahim; Angelina Filice; Maria Pia Brizzi; Francesco Panzuto; Sergio Baldari; Chiara M Grana; Davide Campana; Maria Vittoria Davì; Dario Giuffrida; Maria Chiara Zatelli; Stefano Partelli; Paola Razzore; Riccardo Marconcini; Sara Massironi; Fabio Gelsomino; Antongiulio Faggiano; Elisa Giannetta; Emilio Bajetta; Franco Grimaldi; Mauro Cives; Fernando Cirillo; Vittorio Perfetti; Francesca Corti; Claudio Ricci; Luca Giacomelli; Luca Porcu; Massimo Di Maio; Ettore Seregni; Marco Maccauro; Secondo Lastoria; Alberto Bongiovanni; Annibale Versari; Irene Persano; Maria Rinzivillo; Salvatore Antonio Pignata; Paola Anna Rocca; Giuseppe Lamberti; Sara Cingarlini; Ivana Puliafito; Maria Rosaria Ambrosio; Isabella Zanata; Alessandra Bracigliano; Stefano Severi; Francesca Spada; Valentina Andreasi; Roberta Modica; Federica Scalorbi; Massimo Milione; Giovanna Sabella; Jorgelina Coppa; Riccardo Casadei; Maria Di Bartolomeo; Massimo Falconi; Filippo de Braud Journal: JAMA Netw Open Date: 2022-02-01